Is Osiris Therapeutics, Inc. (OSIR) A Good Stock To Buy?

Page 2 of 2

Now that we’ve mentioned the most bullish investors, let’s also take a look at some funds that said goodbye to their entire stakes in the stock during the third quarter. Intriguingly, Glenn Russell Dubin’s Highbridge Capital Management said goodbye to the biggest stake of all the investors followed by Insider Monkey, comprising close to $0.1 million in stock. Ken Griffin’s fund, Citadel Investment Group, also sold off its call options, about $0.1 million worth.

Let’s now review hedge fund activity in other stocks similar to Osiris Therapeutics, Inc. (NASDAQ:OSIR). These stocks are Gencor Industries, Inc. (DE) (NASDAQ:GENC), Adverum Biotechnologies Inc (NASDAQ:ADVM), Ocular Therapeutix Inc (NASDAQ:OCUL), and Avenue Income Credit Strategies Fund (NYSE:ACP). This group of stocks’ market caps resemble OSIR’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
GENC 4 6637 0
ADVM 11 15276 -4
OCUL 6 6414 -5
ACP 4 6629 1

As you can see these stocks had an average of 6.25 hedge funds with bullish positions and the average amount invested in these stocks was $9 million. That figure was $4 million in OSIR’s case. Adverum Biotechnologies Inc (NASDAQ:ADVM) is the most popular stock in this table. On the other hand Gencor Industries, Inc. (DE) (NASDAQ:GENC) is the least popular one with only 4 bullish hedge fund positions. Osiris Therapeutics, Inc. (NASDAQ:OSIR) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard ADVM might be a better candidate to consider taking a long position in.

Page 2 of 2